Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Gains from Sales and Divestitures (2021 - 2022)

TScan Therapeutics (TCRX) has disclosed Gains from Sales and Divestitures for 2 consecutive years, with $116870.0 as the latest value for Q4 2022.

  • On a quarterly basis, Gains from Sales and Divestitures fell 63.64% to $116870.0 in Q4 2022 year-over-year; TTM through Dec 2022 was $116870.0, a 63.64% decrease, with the full-year FY2022 number at $116870.0, down 63.64% from a year prior.
  • Gains from Sales and Divestitures was $116870.0 for Q4 2022 at TScan Therapeutics, down from $321410.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $321410.0 in Q4 2021 to a low of $116870.0 in Q4 2022.